Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Average Rating of “Moderate Buy” by Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $55.80.

Separately, Oppenheimer raised their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th.

Pelthos Therapeutics Stock Performance

Shares of PTHS opened at $28.36 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The company has a market capitalization of $98.69 million, a price-to-earnings ratio of -1.37 and a beta of 3.10. The company’s 50 day simple moving average is $27.22 and its 200 day simple moving average is $24.96. Pelthos Therapeutics has a 1 year low of $16.50 and a 1 year high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its earnings results on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million for the quarter. On average, sell-side analysts predict that Pelthos Therapeutics will post -12.63 EPS for the current year.

Insiders Place Their Bets

In other Pelthos Therapeutics news, Director Todd C. Davis purchased 35,948 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director owned 75,834 shares in the company, valued at approximately $2,109,701.88. This represents a 90.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 1,638 shares of company stock worth $43,107 in the last quarter. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On Pelthos Therapeutics

Hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC grew its holdings in Pelthos Therapeutics by 279.8% in the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after purchasing an additional 59,435 shares during the period. Knott David M Jr raised its stake in Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after purchasing an additional 1,792 shares during the period. Persistent Asset Partners Ltd boosted its holdings in shares of Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares during the period. Finally, Ikarian Capital LLC raised its position in shares of Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after buying an additional 193,307 shares during the period. 77.96% of the stock is owned by institutional investors and hedge funds.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).